Exploiting Gene Expression Kinetics in Conventional Radiotherapy, Hyperfractionation, and Hypofractionation for Targeted Therapy

详细信息    查看全文

• 作者：Adeola Y. Makinde ; PhD^* ; ^{adeola.makinde@nih.gov" class="auth_mail" title="E-mail the corresponding author} ; Iris Eke ; MD ; PhD^* ; Molykutty J. Aryankalayil ; PhD^* ; Mansoor M. Ahmed ; PhD^&dagger ; ; C. Norman Coleman ; MD^* ; ^&dagger ;
• 刊名：Seminars in Radiation Oncology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：26
• 期：4
• 页码：254-260
• 全文大小：200 K

文摘

The dramatic changes in the technological delivery of radiation therapy, the repertoire of molecular targets for which pathway inhibitors are available, and the cellular and immunologic responses that can alter long-term clinical outcome provide a potentially unique role for using the radiation-inducible changes as therapeutic targets. Various mathematical models of dose and fractionation are extraordinarily useful in guiding treatment regimens. However, although the model may fit the clinical outcome, a deeper understanding of the molecular and cellular effect of the individual dose size and the adaptation to repeated exposure, called multifraction (MF) adaptation, may provide new therapeutic targets for use in combined modality treatments using radiochemotherapy and radioimmunotherapy. We discuss the potential of using different radiation doses and MF adaptation for targeting transcription factors, immune and inflammatory response, and cell “stemness.” Given the complex genetic composition of tumors before treatment and their adaptation to drug treatment, innovative combinations using both the pretreatment molecular data and also the MF-adaptive response to radiation may provide an important role for focused radiation therapy as an integral part of precision medicine and immunotherapy.